A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Summary

The purpose of this study is to characterize the safety of QLS32015 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS32015 injection in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose.

Timeline

Start

2023-06-30

Primary completion

2024-12-31

Completion

2025-08-31

Drugs

Indications